Cooperative roles of Tat & k-cyclin Kaposi's sarcoma
Project Number5R21DE016644-02
Contact PI/Project LeaderLI, MENGTAO
Awardee OrganizationUNIVERSITY OF KENTUCKY
Description
Abstract Text
DESCRIPTION (provided by applicant): Kaposi's sarcoma is a malignant tumor of endothelial origin and the most frequent cancer in AIDS patients. Sixty percent of AIDS-associated KS initiate in the oral cavity, representing a serious problem in oral health. Despite identification of human Herpesvirus 8 (HHV-8) as the etiological agent for all forms of KS, the extraordinarily higher prevalence of KS in HIV-infected patients suggests a cooperative interaction between HIV and HHV-8 in the development of KS. HIV Tat is one of the key regulating factors for viral gene expression and plays many roles in HIV-associated pathogenesis. Tat causes dysfunction and transformation of cultured endothelial cells and induces KS-like lesions in transgenic animals. HHV-8 k-cyclin, a homologue of cellular cyclin D, disrupts cell growth control by aberrantly activating Cdk6 and accelerating the G1/S transition of the cell cycle. The expression of k-cyclin promotes proliferation of endothelial cells. We have found that Tat interacts with k-cyclin in vivo, providing evidence of pathological links between HIV and HHV-8. Here, we propose to study the cooperative roles of Tat and k-cyclin in the development of KS by using immortalized primary endothelial cells. Using this in vitro model, we will dissect steps that are responsible for the HHV-8-infected endothelial cells to progress toward the development of KS malignancy. The specific aims are: (1) define the molecular interaction between Tat and k-cyclin and examine kinase activities associated with these two proteins, (2) determine cooperative effects of Tat and k-cyclin in promoting the proliferation of endothelial cells, (3) demonstrate roles of Tat in enhancing HHV-8 infection and HHV-8-induced cell transformation. These studies will increase our understanding of the pathogenesis of AIDS-associated KS, the cooperative role of Tat and k-cyclin, and suggest a strategy in combating this tumor.
National Institute of Dental and Craniofacial Research
CFDA Code
121
DUNS Number
939017877
UEI
H1HYA8Z1NTM5
Project Start Date
01-June-2005
Project End Date
31-May-2008
Budget Start Date
01-June-2006
Budget End Date
31-May-2008
Project Funding Information for 2006
Total Funding
$175,754
Direct Costs
$122,062
Indirect Costs
$53,692
Year
Funding IC
FY Total Cost by IC
2006
National Institute of Dental and Craniofacial Research
$175,754
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R21DE016644-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R21DE016644-02
Patents
No Patents information available for 5R21DE016644-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R21DE016644-02
Clinical Studies
No Clinical Studies information available for 5R21DE016644-02
News and More
Related News Releases
No news release information available for 5R21DE016644-02
History
No Historical information available for 5R21DE016644-02
Similar Projects
No Similar Projects information available for 5R21DE016644-02